Older HPV Vaccine Reduces Cervical Cancer Rate By Up To 87%, Study Finds

Young women who were vaccinated against the human papillomavirus (HPV) in their teens with an older GlaxoSmithKline product called Cervarix had up to an 87% lower risk of developing virus-related cervical cancer, a study found in English long lasting.
When vaccinated women were 20 years old, those who had received the series of injections between the ages of 12 and 13 had cervical cancer rates 87% lower than unvaccinated women who had been screened for malignancy.

The cancer rate was 62% lower when the injections were given between the ages of 14 and 16 and was reduced by 34% in vaccinated women between the ages of 16 and 18, the researchers reported in the medical journal The Lancet. .

Rates of a precancerous condition were reduced by 97% when the injections were given at ages 12 and 13, the study also found.

HPV 521MCT Prevention

The findings “should greatly reassure those who still doubt the benefits of HPV vaccination,” the researchers said.

The study, funded by Cancer Research UK, looked at registry data from January 2006 to June 2019 on women who had been screened for cervical cancer between the ages of 20 and 64, including women who received the Cervarix vaccine after it became available in 2008.

Over the nearly 13-year period, approximately 28,000 cervical cancer diagnoses and 300,000 diagnoses of a precancerous condition called cervical intraepithelial neoplasia (CIN3) were recorded in England, the data showed.

Young women who were vaccinated had about 450 fewer cases of cervical cancers and 17,200 fewer cases of CIN3 than expected in unvaccinated women of the same age.

“We hope that these new results will stimulate acceptance, as the success of the vaccination program depends not only on the efficacy of the vaccine, but also on the proportion of the population vaccinated,” said co-author Kate Soldan of the Health Security Agency. from United Kingdom.

Cervarix, developed by GSK, protects against two types of HPV that are responsible for approximately 70% to 80% of all cervical cancers.

Since September 2012, Merck & Co’s quadrivalent Gardasil vaccine, which protects against four types of HPV associated with cervical and head and neck cancers, has been used in England in place of Cervarix.

GSK also stopped selling Cervarix in the United States due to low demand with Gardasil dominating the world’s most lucrative market.

Cervical cancer is rare in young women. Follow-up is needed as women age to fully assess the impact of vaccines.


Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *